RenovoRx (RNXT) Q3 2025 earnings review
Commercial Reality Check as Runway Shrinks Before Key Catalyst
RenovoRx is facing a critical execution gap. While the company proved its economics with stellar 80% gross margins on RenovoCath sales, the commercial momentum is Reversing. Q3 revenue dropped 37% sequentially to $266k, breaking management's promise of continuous sequential growth. More alarmingly, the cash position ($10.0M) will only stretch to early 2026, yet the pivotal TIGeR-PaC trial readout isn't expected until 2027. With an ATM offering recently established, near-term dilution is highly likely as the company bridges the gap between early commercialization and final clinical data.
🐂 Bull Case
The razor/razorblade model is validating beautifully. Q3 gross margin hit 80.1%, proving that even small volumes can be highly accretive once sales scale up.
The independent Data Monitoring Committee recommended continuing the Phase III TIGeR-PaC trial following its second interim analysis, signaling confidence in the trial's safety and potential efficacy profile.
🐻 Bear Case
A massive timeline mismatch exists. Cash runway ends in early 2026, but the TIGeR-PaC final data catalyst isn't until 2027. The newly established ATM offering ensures shareholders will pay for this gap.
Despite expanding approved centers to 14, Q3 revenue fell sequentially. Long sales cycles and failure to quickly convert quotes into repeat orders suggest the 'organic demand' narrative was overstated.
⚖️ Verdict: 🔴
Bearish. The combination of Reversing sequential revenue, a shrinking cash runway, and a multi-year wait for pivotal clinical data creates a challenging setup for investors. Dilution appears inevitable.
Key Themes
Revenue Trajectory Contradicts Positive Narrative
In Q1, management confidently guided for 'sequential quarter-over-quarter growth for the foreseeable future.' The data shows this trend is Reversing. Q3 revenue fell 37% to $266k from Q2's $422k. This specific contraction directly contradicts the narrative of accelerating organic demand and highlights the execution risk facing their newly hired sales team.
Cash Runway vs. Clinical Timeline Disconnect
Management stated their $10.0M cash balance will fund operations into early 2026. However, the Phase III TIGeR-PaC trial will not yield final data until 2027. This timeline mismatch guarantees a funding gap. The proactive move to refresh their shelf registration and set up an ATM offering confirms that massive equity dilution is coming before the main value inflection point.
Customer Concentration and Slow Conversion
Sales cycle momentum is Decelerating. While the company boasts 14 approved centers and 10 additional formal quotes, only 5 centers have actually placed repeat orders. Converting the pipeline from 'interested' to 'active purchaser' is taking several months, leaving revenue heavily concentrated in a handful of early adopters.
TAMP Therapy and RenovoCath Innovation
The core technology remains highly differentiated. The Trans-Arterial Micro-Perfusion (TAMP) platform uses the RenovoCath device to isolate blood flow and deliver chemotherapy directly to the tumor under pressure. This specific innovation bypasses systemic toxicity, which historically reduced adverse events by 65% in interim data while improving overall survival from 10 to 16 months.
US-Based Supply Chain Insulates from Macro Shocks
In a challenging macro environment marked by global supply chain disruptions and looming tariff concerns, RenovoRx is well-insulated. The RenovoCath device and most of its components are sourced and manufactured entirely within the U.S. near Chicago. This allows for rapid scaling and Stable COGS without geopolitical exposure.
High Gross Margin Economics
The underlying unit economics are Accelerating toward maturity. Gross margin improved to 80.1% in Q3. Because the commercial business requires minimal marginal cost per unit, any volume growth driven by the new Senior Director of Sales will fall directly to the bottom line, mildly offsetting the clinical cash burn.
Other KPIs
Operating expenses are Accelerating slightly, up from $2.8M in 24Q3. SG&A rose to $1.7M due to the addition of sales personnel and commercialization support, while R&D remained relatively Stable at $1.7M. This burn rate implies the $10.0M cash pile will be exhausted in roughly three quarters if revenue does not scale exponentially.
Trial progress is Stable but slow. The protocol requires 114 randomized patients and 86 events (deaths) for the final analysis. As of the latest update, 95 patients were randomized. The pace of enrollment for the remaining 19 patients is critical to meeting the early 2026 completion target.
Guidance
Management expects the current $10.0M cash balance to be sufficient to fund ongoing commercialization and complete Phase III enrollment in early 2026. This explicitly leaves a gap before the 2027 final data readout.
Targeting completion of the 114-patient enrollment. This timeline has drifted slightly from earlier estimates, but the addition of high-volume centers like Johns Hopkins is expected to push it over the finish line.
The ultimate binary catalyst for the stock. Requires 86 events (patient deaths) to trigger. No interim data will be published before this date to protect trial integrity.
Key Questions
Drivers of Sequential Revenue Decline
Revenue fell from $422k in Q2 to $266k in Q3 despite increasing approved centers. Was this due to lumpy ordering patterns, a lack of re-orders from initial adopters, or disruptions during the transition to a formal sales team?
Bridging the Clinical Funding Gap
With cash running out in early 2026 and pivotal data not due until 2027, what is the exact strategy and expected dilution from the newly established ATM to bridge this 12-to-18 month gap?
Sales Cycle Bottlenecks
You have 24 centers with formal quotes but only 5 placing repeat orders. What are the specific hurdles in the Value Analysis Committee (VAC) process, and how will the new sales director shorten these multi-month lead times?